Merger and Leadership Shift: Recent discussions on X about Recursion Pharmaceuticals (RXRX) have been dominated by the merger with Exscientia, seen by many as a bold step in AI-driven drug discovery. There’s also buzz around the upcoming CEO transition, with opinions split on whether this signals a positive strategic pivot. The chatter reflects curiosity about how these changes will impact future growth.
Clinical Data Excitement: The latest clinical readout from the TUPELO Phase 1b/2 trial for REC-4881 has sparked significant interest on X, with posts highlighting positive results in reducing polyp burden for FAP patients. Many are optimistic about the potential for this to boost confidence in Recursion’s AI platform. Discussions also note plans for FDA engagement in early 2026, adding to the anticipation.
Stock Price Volatility: RXRX’s recent stock price movements, including a notable uptick after the trial data release, are a hot topic on X. Some users express bullishness citing the clinical progress, while others remain cautious due to past volatility and insider selling reports. The community seems actively engaged in debating the stock’s near-term trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
Recursion Pharmaceuticals Insider Trading Activity
Recursion Pharmaceuticals insiders have traded $RXRX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:
- CHRISTOPHER GIBSON (Chief Executive Officer) has made 0 purchases and 11 sales selling 1,238,175 shares for an estimated $6,428,964.
- BLAKE BORGESON sold 220,000 shares for an estimated $961,400
- NAJAT KHAN (Chief R&D Commercial Officer) sold 36,599 shares for an estimated $202,172
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenues of $5.2M in Q3 2025. This is a decrease of -80.16% from the same period in the prior year.
You can track RXRX financials on Quiver Quantitative's RXRX stock page.
Recursion Pharmaceuticals Hedge Fund Activity
We have seen 178 institutional investors add shares of Recursion Pharmaceuticals stock to their portfolio, and 175 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 7,089,386 shares (+63.4%) to their portfolio in Q3 2025, for an estimated $34,596,203
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 3,778,440 shares (+81.9%) to their portfolio in Q3 2025, for an estimated $18,438,787
- VANGUARD GROUP INC added 3,708,975 shares (+10.3%) to their portfolio in Q3 2025, for an estimated $18,099,798
- BLACKROCK, INC. added 3,368,702 shares (+11.9%) to their portfolio in Q3 2025, for an estimated $16,439,265
- FMR LLC removed 2,356,001 shares (-42.2%) from their portfolio in Q3 2025, for an estimated $11,497,284
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 2,183,837 shares (+68.1%) to their portfolio in Q3 2025, for an estimated $10,657,124
- GEODE CAPITAL MANAGEMENT, LLC added 1,847,149 shares (+23.8%) to their portfolio in Q3 2025, for an estimated $9,014,087
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Recursion Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $RXRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 09/11/2025
To track analyst ratings and price targets for Recursion Pharmaceuticals, check out Quiver Quantitative's $RXRX forecast page.
Recursion Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $RXRX recently. We have seen 2 analysts offer price targets for $RXRX in the last 6 months, with a median target of $6.5.
Here are some recent targets:
- Gil Blum from Needham set a target price of $8.0 on 09/11/2025
- Vikram Purohit from Morgan Stanley set a target price of $5.0 on 07/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
